Hemab Therapeutics Holdings, Inc. Common Stock COAG Open Hemab Therapeutics Holdings, Inc. Common Stock in new tab
Hemab Therapeutics Holdings, Inc. Common Stock Analysis (COAG)
Is Hemab Therapeutics Holdings, Inc. Common Stock a good investment? Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is currently trading at 25.00 USD.
Investor FAQ
Does Hemab Therapeutics Holdings, Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Hemab Therapeutics Holdings, Inc. Common Stock?
Hemab Therapeutics Holdings, Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
Company Profile
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Dividends
Historical Split Corporate Actions
Explore Premium Features
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion